S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Why Extreme Networks is a Recession-Proof Technology Play
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double

GSK - GSK Stock Forecast, Price & News

$35.12
-0.18 (-0.51%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$35.10
$35.63
50-Day Range
$33.44
$37.92
52-Week Range
$28.47
$46.97
Volume
4.74 million shs
Average Volume
3.84 million shs
Market Capitalization
$71.89 billion
P/E Ratio
4.30
Dividend Yield
3.70%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.37% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.39mentions of GSK in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
3.32%
From $3.31 to $3.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

155th out of 1,049 stocks

Pharmaceutical Preparations Industry

67th out of 514 stocks


GSK stock logo

About GSK (NYSE:GSK) Stock

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

How Could GSK's RSV Vaccine Change its Valuation? (GSK)
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
GSK (GSK) Set to Announce Quarterly Earnings on Wednesday
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
StockNews.com Upgrades GSK (NYSE:GSK) to "Strong-Buy"
GSK falls Tuesday, underperforms market
GSK rises Wednesday, outperforms market
GSK plc (NYSE:GSK) Short Interest Down 22.8% in December
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
3 Must Have Pharma Stocks in January 2023
Why I’d buy GSK shares in 2023
GSK, Sanofi COVID booster vaccine gets approval in UK
GSK rises Thursday, outperforms market
Should You Hold GSK plc (GSK) Shares?
GSK Shares Drop as Cancer Drug Disappoints
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings
11/02/2022
Ex-Dividend for 1/12 Dividend
11/17/2022
Dividend Payable
1/12/2023
Today
1/30/2023
Next Earnings (Confirmed)
2/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
90,096
Year Founded
2000

Profitability

Net Income
$6.03 billion
Pretax Margin
15.33%

Debt

Sales & Book Value

Annual Sales
$38.44 billion
Cash Flow
$3.60 per share
Book Value
$13.62 per share

Miscellaneous

Outstanding Shares
2,047,099,000
Free Float
1,842,389,000
Market Cap
$71.89 billion
Optionable
Optionable
Beta
0.66

Social Links


Key Executives

  • Emma N. WalmsleyEmma N. Walmsley
    Chief Executive Officer & Executive Director
  • Iain James MackayIain James Mackay
    Chief Financial Officer & Executive Director
  • Jon Ellis
    VP & Head-Technology Business Development
  • Tony Wood
    Chief Scientific Officer
  • Shobie Ramakrishnan
    Chief Digital & Technology Officer













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 on January 1st, 2023. Since then, GSK stock has decreased by 0.1% and is now trading at $35.12.
View the best growth stocks for 2023 here
.

Are investors shorting GSK?

GSK saw a decrease in short interest in the month of December. As of December 30th, there was short interest totaling 8,430,000 shares, a decrease of 22.8% from the December 15th total of 10,920,000 shares. Based on an average trading volume of 5,660,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.4% of the company's stock are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our GSK earnings forecast
.

How can I listen to GSK's earnings call?

GSK will be holding an earnings conference call on Wednesday, February 1st at 6:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, November, 2nd. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.19. The pharmaceutical company had revenue of $9.22 billion for the quarter, compared to analysts' expectations of $7.75 billion. GSK had a trailing twelve-month return on equity of 32.18% and a net margin of 37.88%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, November 2nd. Investors of record on Friday, November 18th will be paid a dividend of $0.3695 per share on Thursday, January 12th. This represents a $1.48 annualized dividend and a dividend yield of 4.21%. The ex-dividend date is Thursday, November 17th.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.31 per share and currently has a dividend yield of 3.71%. The dividend payout ratio is 16.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 38.30% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.67 billion-$51.60 billion, compared to the consensus revenue estimate of $32.29 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (0.88%), Douglas Lane & Associates LLC (0.10%), National Bank of Canada FI (0.02%), Keystone Financial Planning Inc. (0.01%), Natixis Advisors L.P. (0.01%) and Jacobs & Co. CA (0.01%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $35.12.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $71.89 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $8.16 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 1/31/2023 by MarketBeat.com Staff